Jump to navigation Jump to search
|Chemical and physical data|
|Molar mass||479.03524 g/mol|
|3D model (JSmol)|
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.
- Solt LA; Wang Y; Banerjee S; Hughes T; Kojetin DJ; Lundasen T; Shin Y; Liu J; Cameron MD; Noel R; Yoo SH; Takahashi JS; Butler AA; Kamenecka TM; Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature. 485 (7396): 62–8. doi:10.1038/nature11030. PMC 3343186. PMID 22460951. Lay summary – Nature Magazine.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|